Fabhalta (Iptacopan) for PNH

Overview
Fabhalta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is also known by its drug name, iptacopan.

Fabhalta is a complement inhibitor. Fabhalta is a small molecule believed to work by binding to factor 5, preventing the activation of complement proteins C3 and C5. The complement cascade is part of the immune system that attacks red blood cells in PNH.

How do I take it?
Fabhalta is taken orally twice daily. Fabhalta is available in capsule form.

Side effects
The FDA-approved label for Fabhalta lists common side effects including headache, upper respiratory symptoms, diarrhea, abdominal pain, bacterial infections, viral infections, nausea, and rash.

Rare but serious side effects listed for Fabhalta include serious and life-threatening bacterial infections, even if you’ve previously been vaccinated against that particular bacterium. Fabhalta can also cause elevated levels of cholesterol.

For more details about this treatment, visit:

Fabhalta — Novartis
https://www.fabhalta.com/